Ann: Update of put option and loan repayment recovery, page-165

Well the big question about the Galderma non-disclosure is not about the actual contract but the pattern of behaviour it exposed - that made QIN uninvestible.

Future value is still predicated on QIN developing a huge new market for their product when they couldn't even sell their tiny harvest without pulling forward demand from an existing customer at a discount.

$100m won't fix it, I don't think $300m would either.